TwinBeech Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

TwinBeech Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,700	Closed	-$185K	–	573
2025 Q4	$185K	Sell	23,700 -172,037	-88%	-$1.24M	0.01%	546
2025 Q3	$1.49M	Buy	+195,737	New	+$1.63M	0.06%	264
2025 Q2	–	Sell	-83,470	Closed	-$626K	–	651
2025 Q1	$626K	Buy	+83,470	New	+$673K	0.01%	555
2023 Q2	–	Sell	-385,208	Closed	-$3.21M	–	600
2023 Q1	$3.21M	Buy	+385,208	New	+$3.71M	0.07%	306
2022 Q4	–	Sell	-250,517	Closed	-$3.16M	–	693
2022 Q3	$3.16M	Buy	+250,517	New	+$3.22M	0.08%	264

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

TwinBeech Capital's BCRX Position: Q1 2026 in Review

TwinBeech Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 23,700 shares — an estimated $185K sold.

TwinBeech Capital first reported a position in BCRX in Q3 2022 and held it in 5 quarters. The position peaked at $3.21M in Q1 2023. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

TwinBeech Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 23,700 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $185K.
TwinBeech Capital first reported a position in BioCryst Pharmaceuticals in Q3 2022 and held it in 5 quarters.
TwinBeech Capital's BioCryst Pharmaceuticals position peaked at $3.21M in Q1 2023.
302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.